Table 4 Disposition of polymorphisms involved in nevirapine metabolism
| Â | Total | Hepatotoxicity | No hepatotoxicity | p* |
|---|---|---|---|---|
n = 362 | n = 8 | n = 354 | ||
ABCB1 c.3435/rs1045642, n (%) | Â | Â | Â | 0.019 |
 CC | 86 (23.8) | 5 (5.8) | 81 (94.2) |  |
 CT | 178 (49.2) | 1 (0.6) | 177 (99.4) |  |
 TT | 98 (27.0) | 2 (2.0) | 96 (98.0) |  |
CYP2B6 c.516/rs3745274, n (%) | Â | Â | Â | 0.706 |
 GG | 196 (54.1) | 6 (3.1) | 190 (96.9) |  |
 GT | 141 (39.0) | 2 (1.4) | 139 (98.6) |  |
 TT | 25 (6.9) | 0 (0.0) | 25 (100.0) |  |
CYP3A4/A5 **, n (%) | Â | Â | Â | 0.602 |
 Extensive | 58 (16.1) | 0 (0.0) | 58 (100.0) |  |
 Intermediate | 270 (74.5) | 8 (3.0) | 262 (97.0) |  |
 Poor | 25 (6.9) | 0 (0.0) | 25 (100.0) |  |
 nd | 9 (2.5) | 0 (0.0) | 9 (100.0) |  |